Neuro Event Labs

Neuro Event Labs: problem, solution and market

Management

Neuro Event Labs is led by a team with long experience in MedTech, software and epilepsy care, supported by an active board of industry and investor representatives. The team combines commercial, technical and clinical experience, which is important for scaling a regulated MedTech solution in Europe and the US.

Board of Directors

Company structure

Distribution of company shares

The shareholder base of Neuro Event Labs consists mainly of specialist life science venture funds, the EU’s EIC Fund and an employee option pool for founders and key team members. Hadean Ventures is the largest owner through two funds, with the EIC Fund and Maki.vc also holding significant stakes.

*Percentages are shown before the current equity round.*

Back to top ▲

Use of funds/funding scenarios

The final use of funds depends on how much is raised in this round. The table below shows three scenarios based on different levels of Invesdor participation alongside the anchor investors, who together have committed €500,000. The total round is planned between €1,000,000 and €2,000,000, of which €500,000–€1,500,000 is expected to come through Invesdor.

In all scenarios, the funds will be used to scale the seizure‑monitoring system in Europe, prepare and launch it in the US home market, further improve the AI detection capabilities and integrate the product more deeply into partner hospital and monitoring systems.

Back to top ▲

Exit scenarios

Neuro Event Labs is building a business that could be attractive to strategic buyers and financial investors once it has scaled in Europe and the US. The company follows a typical MedTech path where exits often happen through acquisitions by larger industry players or specialist healthcare funds.

Back to top ▲

Risk summary (simplified)

Investments in growth companies always involve risks. You can lose part or all of the money you invest.

The following text is a short and strongly simplified overview of selected risks of an investment in Neuro Event Labs.
It is not complete and does not replace the detailed description of risks in the Key Investment Information Sheet (KIIS).

Before you invest, you must read the KIIS in full and with care and check whether you can understand and bear all of the risks described there.
If there are any differences between this summary and the KIIS, only the KIIS is legally binding.

• Business, market and management risk
  NEL is still at an early growth stage. Revenues from pharma research projects are volatile because contracts are often agreed project‑by‑project, not on a long‑term basis. Growth in the hospital and home monitoring segments also depends heavily on third‑party distribution partners that NEL cannot fully control. At the same time, a relatively small team is handling product development, regulatory work, clinical studies, sales and a new US market launch in parallel, which can lead to delays and execution errors. Even though the Nelli product already generates revenue and has received an FDA Breakthrough Device Designation, there is still a risk that it will not receive full FDA clearance. Overall, this can significantly reduce revenues and company value and, in the worst case, lead to a total loss of your invested capital.
• Sector, regulatory, funding and platform risk
  Demand for NEL’s products and services depends on the general market environment, technological developments and other industries that NEL cannot influence. In addition, NEL operates in a highly regulated health and medtech environment; changes in laws or non‑compliance with regulations may result in sanctions and harm the business. NEL may need additional funding to execute its growth plans and might not be able to raise it at all or only on unfavourable terms. There is also a risk that the crowdfunding platform is temporarily or permanently unavailable or ceases operations. This can cause delays in subscriptions, payment processes or repayments due to revocations, even though your contractual rights in principle remain in place.
• Default, return and liquidity risk
  If NEL cannot implement its growth strategy as planned, fails to win enough contracts or cannot secure further funding, the company may face financial difficulties or insolvency. In such a case, distributions, repayments or a later share sale may be lower than expected, delayed or may not occur at all – up to a complete loss of your invested capital. NEL’s valuation and financial projections are based on assumptions that may prove too optimistic. As a growth‑oriented company, NEL may retain profits instead of paying dividends, so investors may receive no or only limited cash returns. The shares are not listed on a stock exchange, there is no active secondary market and transferability is restricted. You may therefore have to hold your investment for a long time or may only be able to sell at a financial loss.
• Shareholder, dilution, exit and structural risks
  As a minority shareholder, you have only limited influence on key decisions and NEL’s business strategy; majority shareholders can pass resolutions that negatively affect your investment. Future capital increases may dilute your shareholding if you do not, or cannot, participate in later funding rounds. Any return may depend largely on a future sale of the company or an IPO; there is a risk that such an exit does not occur or happens at a lower valuation than expected. Contractual tag‑along and drag‑along provisions may require you to sell your shares at a time or on terms that do not match your preferences. In addition, NEL’s success depends heavily on its management team and qualified employees; the loss of key personnel or difficulties in hiring and retention can weaken business performance.

A complete and detailed description of all risk factors can be found only in the KIIS in the documents section of this funding round

Back to top ▲

Note:

In this update section you will find new, project-relevant information that we receive.

Invesdor does not conduct a separate review of information received after the start of the financing phase.

UPDATE on 24.09.2026 | New pharma agreement creates commercial momentum

For pharmaceutical companies, this creates both scientific and financial value: more complete data, additional outcome measures and a stronger basis for evaluating treatment efficacy, without relying solely on patient-reported events.

The agreement strengthens Neuro Event Labs’ ambition to establish Nelli as a standard monitoring tool in epilepsy clinical trials and expands the company’s coverage across pharmaceutical research programmes.

For investors, this is more than a new customer announcement. It is evidence that Nelli is being integrated into the development process of a pharmaceutical treatment, creating a potential path from individual contracts to repeatable adoption across clinical trials.

“This agreement demonstrates the value Nelli can bring to pharmaceutical research. By objectively measuring seizures and sleep-related events, Nelli helps generate richer data for treatment development and supports our ambition to establish it as a standard tool in epilepsy clinical trials.”

Martijn Wallert, CEO, Neuro Event Labs

UPDATE on 22.09.2026 Backed by a specialist life-science investor

Neuro Event Labs is backed by Hadean Ventures, a European venture capital manager focused on science-driven healthcare and life-science companies addressing unmet medical needs.

Hadean states that it has more than €230 million in assets under management and a team combining scientific, technical, investment and start-up experience. Its portfolio includes Cardior Pharmaceuticals, acquired by Novo Nordisk; Themis Bioscience, acquired by MSD; Abliva, acquired by Pharming; and SAGA Diagnostics, which entered into an agreement to be acquired by Foundation Medicine, an independent Roche subsidiary. View Hadean’s portfolio
Hadean also lists Neuro Event Labs among its investments in digital health and neurology.

For investors, this provides important context: Neuro Event Labs is not an isolated early-stage concept. It has attracted backing from a specialist healthcare investor with experience in complex, regulated technologies and companies addressing significant medical needs.
 

UPDATE on 15.09.2026 See why objective data can make a difference

Epileptic seizures often occur at home and at night – precisely when no medical professional is present. When patients later have to describe what happened, important details may be missing or recalled inaccurately. This makes it more difficult for clinicians to assess the seizure and decide on the next steps in treatment.

Nelli addresses the point where seizures actually occur: using a camera and artificial intelligence, the system objectively detects and classifies motor seizures.In the video, Professor Jukka Peltola from Tampere University explains the challenges of current epilepsy diagnostics and how Nelli can help address them.

Watch the video to learn more about the potential role this technology could play in the future of epilepsy care.

UPDATE on 11.09.2026: Investor questions around the funding round

We have received questions from investors about Neuro Event Labs, including shareholder rights, financing, financial projections, the US market, and Nelli’s FDA status. We have addressed these questions to the best of our ability based on the information provided by the company.

UPDATE on 10.09.2026 | How Nelli contributed to the right treatment for Martta

Living with epilepsy impacts much more than just the moments when a seizure occurs. It can affect sleep, daily life and the sense of safety, both for people living with epilepsy and for those around them.

With nocturnal seizures, there is an additional challenge: they can be difficult to observe. As a result, it is not always easy for patients and their loved ones to accurately describe what happens during the night. For doctors, this can also make it difficult to get a complete picture of the seizures and adjust treatment accordingly.

Martta (21) has lived with epilepsy since she was four. After years of nocturnal seizures, her family decided to use Nelli, Neuro Event Labs’ AI-powered, contact-free seizure monitoring system, at home. Over the course of 28 nights, Nelli collected data on her nocturnal seizures.

The data gave Martta’s doctors new insights into what was actually happening during the night. This enabled them to better assess her epilepsy and make more informed decisions about her treatment.

And for Martta, this made a real difference:

“With the help of Nelli, we discovered a new drug that has decreased my nocturnal seizures. Without it, we wouldn’t have known.”

Martta’s story shows what can happen when we look beyond what is visible or remembered during the day and also gain insight into what happens during the night.

Better data can lead to better decisions. And ultimately, to treatment that better fits the patient’s daily life.

Watch Martta’s story in the video below.

UPDATE on 03.09.2026: The groundwork is paid for. This round funds the scaling.

Most MedTech raises ask investors to fund the science. This one does not.

Neuro Event Labs has already carried Nelli - its AI-powered, contact-free seizure-monitoring system - through the most costly and highest-risk stages of MedTech development: regulatory clearance and real-world clinical use.

Where Nelli stands today

• CE-marked as a Class IIa medical device in Europe
• FDA 510(k) cleared for use in U.S. hospitals
• 7,000+ patients monitored across 60+ hospitals
• 1M+ hours of clinical recordings underpinning the technology
• €1.2M revenue in 2025, €6.5M cumulative revenue to date

This is not a research-stage device seeking validation. It is a validated, regulated platform already generating revenue in the market.

What this round funds

Capital raised in this round is directed entirely at commercial growth, not further development:

1. Expand in Europe: scale Nelli across hospitals and into home monitoring
2. Enter the U.S.: go to market through established partners
3. Deepen partnerships: grow relationships with pharmaceutical companies, CROs and eDiary providers

The investment case

Investors backing this round are not funding an unproven concept. They are supporting the next phase of a clinically validated, regulated and increasingly commercialised MedTech platform with real-world use, early revenue and multiple routes to scale.

The science is de-risked. The market opportunity is what's left to capture.